VERIGRAFT Revenue and Competitors

👉 Right now there is a unique opportunity for private individuals to join us, through our crowdfunding campaign. More info at https://capitalcell.com/en/campaign/verigraft/ \n \nVERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.